Retatrutide, an investigational triple hormone receptor agonist from Eli Lilly and Company, has demonstrated significant clinical efficacy in recent Phase 3 trials. According to data presented at the American Diabetes Association (ADA) 86th Scientific Sessions, the treatment delivered substantial weight loss and improvements in type 2 diabetes, knee osteoarthritis pain, and obstructive sleep apnea. Results from the TRIUMPH-1 and TRANSCEND-T2D-1 trials were reported in June 2026.
How does retatrutide impact weight loss and BMI?
In the TRIUMPH-1 trial, participants receiving a 12 mg dose of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks. According to Eli Lilly and Company, 65.3% of those on the 12 mg dose reached a BMI below 30, effectively moving them out of the obesity category, while 33.3% achieved a “healthy” BMI of less than 25. For participants with a baseline BMI of 35 or higher who entered a 104-week extension, the average weight loss reached 85.0 lbs (30.3%).
What are the effects on obesity-related complications?
Beyond weight reduction, retatrutide showed measurable benefits for common comorbidities. In TRIUMPH-1, patients with knee osteoarthritis saw their WOMAC pain subscale scores drop by up to 4.3 points (73.1%). Those with moderate-to-severe obstructive sleep apnea experienced a reduction of up to 36.1 events per hour (60.6%) on the apnea-hypopnea index (AHI), according to company reports.
For adults with type 2 diabetes, the TRANSCEND-T2D-1 trial—simultaneously published in The Lancet—showed that participants achieved A1C reductions of up to 2.0% at 40 weeks. Up to 46% of these participants reached an A1C below 5.7%, which is the threshold for normoglycemia.
How does retatrutide compare to other treatments?
The clinical results highlight a shift toward treating obesity and its complications through a single, triple-action therapy. Dr. Ania Jastreboff, lead investigator and professor at the Yale School of Medicine, noted that obesity is a chronic disease and that these findings demonstrate the potential of treating the underlying neurometabolic biology. Unlike historical approaches that managed conditions in “silos,” this triple hormone receptor agonist targets GIP, GLP-1, and glucagon simultaneously.
| Metric | TRIUMPH-1 (80 Weeks) | TRANSCEND-T2D-1 (40 Weeks) |
|---|---|---|
| Max Weight Loss | 70.3 lbs (28.3%) | 36.6 lbs (16.8%) |
| Systolic BP Reduction | Up to 12.3 mmHg | Up to 6.4 mmHg |
Frequently Asked Questions
Is retatrutide currently available to the public?
No. According to Eli Lilly and Company, retatrutide is an investigational molecule that is legally available only to participants enrolled in the company’s clinical trials.
What were the most common side effects observed in the trials?
The safety profile was consistent with other incretin-based therapies. Common adverse events included nausea, diarrhea, vomiting, and constipation. Discontinuation rates due to adverse events in the 12 mg dose group were 11.3% in TRIUMPH-1 and 5.1% in TRANSCEND-T2D-1, according to the June 2026 announcement.
Does retatrutide improve cardiovascular risk factors?
Yes. Both trials showed significant improvements in cardiovascular risk markers, including reductions in triglycerides, non-HDL cholesterol, and systolic blood pressure.
Are you interested in the future of cardiometabolic health? Subscribe to our newsletter for the latest updates on clinical trial breakthroughs and medical research developments.
